La chaîne d'options affiche les données clés des options sur actions de Pasithea Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Pasithea Therapeutics..

Pasithea Therapeutics (NASDAQ:KTTA) Stock, Chaîne d'Options

Pasithea Therapeutics

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics Corp

Sunoco LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUN#NYSE">SUN</a>) reported first-quarter revenues of $5.18 billion, which missed <a href="https://www.benzinga.com/pressreleases/25/05/n45217061/sunoco-lp-reports-first-quarter-2025-financial-and-operating-results" target="_blank" rel="noreferrer noopener">the consensus of $5.58 billion</a>. EPS of $1.21 missed <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">the consensus of $1.52</a>.
The adjusted distributable cash flow of&nbsp;$310 million was higher than&nbsp;the $176 million a year ago. Adjusted EBITDA increased to&nbsp;$458 million from&nbsp;$242 million a year ago.
The Fuel Distribution segment sold around 2.1 billion gallons of fuel (broadly flat&nbsp;year over year), with the fuel margin for all gallons sold at 11.5 cents per gallon versus 10.9 cents per gallon in the prior year quarter.
Adjusted EBITDA&nbsp;for the Fuel Distribution segment declined to&nbsp;$220&nbsp; million&nbsp;compared to&nbsp;$218&nbsp;million&nbsp;in the prior year quarter.
Total capital expenditures were&nbsp;$101 million, including&nbsp;$75 million&nbsp;for growth capital and&nbsp;$26 million&nbsp;for maintenance capital.
On&nbsp;April 23, Sunoco&nbsp;declared a distribution of&nbsp;$0.8976&nbsp;per unit, an increase of approximately 1.25% sequentially, payable on May 20, to unitholders of record as of May 9, 2025.
As of March 31, the company had long-term debt of about&nbsp;$7.7 billion&nbsp;and no borrowings outstanding on its&nbsp;$1.5 billion&nbsp;revolving credit facility.
On Monday, the company agreed to acquire&nbsp;Parkland Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PKIUF#OTC">PKIUF</a>)&nbsp;in a deal valued at <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/05/45194533/sunoco-fuels-up-with-9-1b-parkland-deal-eyes-10-cash-flow-bump" rel="noreferrer noopener">approximately $9.1 billion, including debt</a>.
Investors can gain exposure to the stock via&nbsp;the InfraCap MLP ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMZA#NYSE">AMZA</a>) and&nbsp;the Alerian MLP ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMLP#NYSE">AMLP</a>).
Price Action: SUN&nbsp;shares closed lower by&nbsp;1.52%&nbsp;at&nbsp;$53.74 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/reiteration/25/05/45207000/analysts-still-like-chevron-cite-strong-fcf-balance-sheet-as-key-amid-opec-and-recession-fears" target="_blank" rel="noreferrer noopener">Analysts Still Like Chevron, Cite Strong FCF &amp; Balance Sheet As Key Amid OPEC And Recession Fears</a></li>
</ul>
Photo via Shutterstock

Earnings

Equities

Large Cap

News

AMLP

AMZA

PKIUF

Why Did Sunoco Stock Fall After Q1 Earnings?

WestPark Capital analyst Curtis Shauger initiated coverage of Workday Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) on Monday with a <a href="https://www.benzinga.com/quote/WDAY/analyst-ratings">Buy rating</a> and announced a price forecast of $315.00.
Workday was founded in 2005 by Dave Duffield and Aneel Bhusri, both veterans of PeopleSoft. Their goal was to disrupt the vast enterprise resource planning (ERP) market through cloud-based solutions.
Initially successful in human capital management (HCM), the company has since expanded into financial software. 
The analyst noted that despite surpassing an $8 billion annual revenue run rate, WDAY holds only about 2% of the $100 billion-plus ERP market, signaling significant growth potential.
Workday's growth momentum has eased as legacy ERP providers resist and the financials sector slows down its adoption of cloud technology.
Also Read: <a href="https://www.benzinga.com/25/05/45207560/expedia-faces-turbulence-as-us-travel-trend-weakens-says-analyst">Expedia Faces Turbulence As US Travel Trend Weakens, Says BofA Analyst</a>
The company's rapid early success in human capital management (HCM) was aided by limited competition and a strong fit for cloud-based tools. 
However, by the time Workday expanded into financials, major rivals like Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) and Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) had already introduced their own cloud offerings, making market penetration more challenging, noted Shauger.
Workday's AI strategy, introduced under the "Illuminate" banner at last year's Rising conference, is beginning to take form, but its impact on revenue remains uncertain. 
The company has started monetizing select AI agents, yet much of its approach centers on integrating AI into existing products to boost demand and accelerate deal closures. 
Recent workforce reductions at Workday demonstrate management's focus on balancing profitability with growth. After cutting 3% of staff in 2023 and another 8% this year, Shauger views these proactive decisions as positive steps.
With shares trading at historically low valuations, investors may be overlooking potential upside from Workday's AI initiatives. He said that if its AI strategy spurs even moderate growth, the stock could re-rate significantly.
Price Action: WDAY shares traded lower by 0.036% at $248.28 at last check Tuesday.
Read Next: <a href="https://www.benzinga.com/25/05/45194848/footwear-giant-skechers-to-go-private-in-more-than-9b-deal-with-3g-capital-stock-surges">Footwear Giant Skechers To Go Private At 30% Premium In PE Deal</a>
Photo: Shutterstock

Price Target

Initiation

Analyst Ratings

General

MSFT

ORCL

WDAY

Workday Could Soar With AI Strategy, Says Analyst

Astronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRO#NASDAQ">ATRO</a>) affirms FY2025 sales outlook from $820.00 million-$860.00 million to $820.00 million-$860.00 million vs $834.22 million estimate.

Guidance

ATRO

Astronics Affirms FY2025 Sales Guidance of $820.00M-$860.00M vs $834.22M Est

Macro Notification

Commodities

Econ #s

Markets

API Weekly Crude Oil Stock: 4.49M Barrel Draw vs 2.5M Barrel Draw Est.

WIIM

HALO

Halozyme Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 guidance.

Douglas Emmett (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEI#NYSE">DEI</a>) affirms FY2025 FFO guidance from $1.42-$1.48 to $1.42-$1.48 vs $1.45 analyst estimate..

Douglas Emmett Affirms FY2025 FFO Guidance of $1.42-$1.48 vs $1.45 Est

The Mosaic Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) is advancing its strategy to redefine growth, and is proud to announce a successful biostimulant product launch in China. Neptunion is our newest biostimulant product - it helps crops address abiotic pressures such as drought, salinity and heat by adding stress resistant properties into water soluble fertilizers. Our Mosaic Biosciences product line offers sustainable ag technology to enable growers to improve yields while minimizing environmental impacts.
"The launch of Neptunion in China is a significant step in advancing our Mosaic Biosciences business," says Jenny Wang, EVP Commercial. "We remain committed to expanding our market access and maximizing ag productivity through biological products that enhance the value we provide to farmers and help the world grow the food it needs."
This product is currently undergoing the registration process in India and Brazil.

Mosaic Biosciences Announces Launch Of Neptunion In China

MASI

Masimo shares are trading lower. The company reported Q1 financial results and announced the sale of its consumer audio business for $350 million.

Astronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRO#NASDAQ">ATRO</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.28 by 57.14 percent. This is a 588.89 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $205.94 million which beat the analyst consensus estimate of $192.53 million by 6.97 percent. This is a 11.27 percent increase over sales of $185.07 million the same period last year.

Earnings Beats

Astronics Q1 Adj. EPS $0.44 Beats $0.28 Estimate, Sales $205.94M Beat $192.53M Estimate

Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.47) by 10.64 percent. This is unchanged from the same period last year.

PRLD

Prelude Therapeutics Q1 EPS $(0.42) Beats $(0.47) Estimate

Douglas Emmett (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEI#NYSE">DEI</a>) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate of $0.39 by 2.56 percent. This is a 11.11 percent decrease over earnings of $0.45 per share from the same period last year. The company reported quarterly sales of $251.53 million which beat the analyst consensus estimate of $246.46 million by 2.06 percent. This is a 2.68 percent increase over sales of $244.97 million the same period last year.

Douglas Emmett Q1 FFO $0.40 Beats $0.39 Estimate, Sales $251.53M Beat $246.46M Estimate

Energy markets are caught in a whirlwind of uncertainty. Tariffs, shifting tanker routes, and geopolitical risks have made volatility the only constant. Traditional forecasts, which banked on low energy prices this year, are now shaky at best. A sudden potential maritime conflict, burning through vast amounts of fuel, could easily upend these projections, leaving investors scrambling to adapt.
<h2 class="wp-block-heading">Renewables Outshine Traditional Oil</h2>
Investment dollars are increasingly flowing into renewable energy as global economies double down on carbon neutrality goals. With an oversupply looming, new oil projects are quietly fading. While exploration and drilling costs have dipped, the financial strain of keeping the oil sector competitive-coupled with tighter environmental rules-keeps climbing. Even U.S. shale, once a beacon of energy independence, struggles to match renewables on cost. Capital isn't wavering anymore; green energy offers better returns. Oil's heavy legacy costs and regulatory hurdles are testing investor patience to its limits. Adding to oil's woes, a potential U.S.-Iran nuclear deal could flood the market with an extra two million barrels per day. If that happens, Brent prices might slide toward $50, forcing OPEC+ and U.S. producers to slash output-a looming risk for the entire industry.
<h2 class="wp-block-heading">Europe's Quest for Energy Independence</h2>
European nations are pushing hard to diversify their energy imports. The EU's import landscape has shifted dramatically in recent years. In 2024, the U.S. emerged as the bloc's top supplier of liquefied natural gas (LNG) and distillates, while Norway solidified its role as the leading provider of pipeline gas, according to Eurostat data. This pivot away from historical suppliers has slashed fossil fuel imports from certain regions by over 80% by late 2023. Yet, this newfound independence comes at a steep price. After price caps were lifted, EU energy bills surged 12% on average, with January 2023 alone seeing a 16% spike. For European consumers, inflation has become the steep cost of energy security.
<h2 class="wp-block-heading">OPEC+ Faces a Balancing Act</h2>
OPEC+ finds itself in a tight spot. The oil cartel aims to hold its ground in the global market and avoid a sharp, lasting drop in prices, all while maintaining ties with major buyers like India, Europe, and China-each with their own agendas. Starting April 2025, OPEC+ plans to boost production by 411,000 barrels per day, a move driven by the need to secure market share amid trade frictions. The group isn't as worried about price dips as it is about losing ground to the U.S., where shale production remains a persistent challenge.
This ramp-up has already rattled markets. Crude prices fell below $69, the lowest since March 11, following the Trump administration's <a href="https://www.whitehouse.gov/presidential-actions/2025/03/imposing-tariffs-on-countries-importing-venezuelan-oil/">sanctions on Venezuelan oil</a> in March. Those sanctions forced companies like Global Oil to pull out, with Chevron having exited earlier, leaving Venezuela increasingly isolated. This disruption threatens supply chains and raises doubts about the country's oil industry survival. 
<h2 class="wp-block-heading">Looking Ahead to Energy Markets</h2>
The global energy landscape is shifting in real time. Supply chains are rerouting, partnerships are fraying, and climate goals are bending under pressure. One thing is clear: the era of predictable, cheap energy is gone. Investors, who see volatility as a blip, risks to be left behind. Going through the points in thesis and briefly, let&#8217;s note the following: -Price Swings Intensify: Geopolitical tensions will keep oil and gas prices on a rollercoaster. -Trade Routes Evolve: Traditional energy flows face ongoing disruptions as Europe seeks new import sources. -Green Energy Gains Ground: Despite the new U.S. administration's stance, investments in renewables surge globally. -Resource Rivalries Heat Up: Major economies will compete fiercely for reliable energy supplies. -Strategic Reserves in Play: Governments may tap oil and gas reserves to counter price spikes from trade disputes. Energy markets in 2025 are a test of resilience. Investors should actively adapt if they don&#8217;t want to fall by the wayside.

Global

Opinion

Trading Ideas

Renewables Outpace Oil In Attracting Investments

UPST

Upstart Holdings shares are trading lower after the company issued Q2 sales guidance below estimates.

Ardent Health Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARDT#NYSE">ARDT</a>) affirms FY2025 GAAP EPS guidance from $1.73-$2.01 to $1.73-$2.01 vs $1.90 analyst estimate. Affirms FY2025 sales outlook from $6.20 billion-$6.45 billion to $6.20 billion-$6.45 billion vs $6.33 billion estimate.

ARDT

Ardent Health Partners Affirms FY2025 GAAP EPS Guidance of $1.73-$2.01 vs $1.90 Est; Affirms FY2025 Sales Guidance of $6.20B-$6.45B vs $6.33B Est

Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.08 by 37.5 percent. This is a 21.43 percent decrease over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $89.88 million which missed the analyst consensus estimate of $90.70 million by 0.90 percent. This is a 10.19 percent decrease over sales of $100.08 million the same period last year.

Earnings Misses

FORR

Forrester Res Q1 Adj. EPS $0.11 Beats $0.08 Estimate, Sales $89.88M Miss $90.70M Estimate

Vestis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $0.14 by 135.71 percent. This is a 138.46 percent decrease over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $665.25 million which missed the analyst consensus estimate of $690.03 million by 3.59 percent. This is a 5.69 percent decrease over sales of $705.37 million the same period last year.

VSTS

Vestis Q2 Adj. EPS $(0.05) Misses $0.14 Estimate, Sales $665.25M Miss $690.03M Estimate

SMCI

Super Micro Computer shares are trading lower after the company reported worse-than-expected Q3 financial results, issued Q4 guidance below estimates, and cut its FY25 sales guidance.

CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) reported quarterly losses of $(1.58) per share which missed the analyst consensus estimate of $(1.25) by 26.4 percent. This is a 10.49 percent decrease over losses of $(1.43) per share from the same period last year. The company reported quarterly sales of $865.00 thousand which missed the analyst consensus estimate of $6.39 million by 86.46 percent. This is a 71.63 percent increase over sales of $504.00 thousand the same period last year.

CRSP

CRISPR Therapeutics Q1 EPS $(1.58) Misses $(1.25) Estimate, Sales $865.00K Miss $6.39M Estimate

Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.10) by 130 percent. This is a 50 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $70.64 million which beat the analyst consensus estimate of $67.39 million by 4.82 percent. This is a 32.31 percent increase over sales of $53.39 million the same period last year.

Viant Technology Q1 Adj. EPS $0.03 Beats $(0.10) Estimate, Sales $70.64M Beat $67.39M Estimate

SuRo Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSSS#NASDAQ">SSSS</a>) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 23.08 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $499.09 thousand which missed the analyst consensus estimate of $1.20 million by 58.41 percent. This is a 67.34 percent decrease over sales of $1.53 million the same period last year.

SSSS

SuRo Capital Q1 GAAP EPS $(0.16) Misses $(0.14) Estimate, Sales $499.09K Miss $1.20M Estimate

Health Care

Press Releases

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Power Nickel's (TSX.V: PNPN) Hole Delivers "BIG"- Gold Terra (TSX.V: YGT) Developments and Exploration Progress Reported – More Stocks Inside!

Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

KTTA

KTTAW

OGEN

PNPNF

TSXV:PNPN

TSXV:YGT

YGTFF

Alzamend Neuro

Azitra

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Galecto

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Oragenics

Palisade Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Plus Therapeutics

Sunshine Biopharma

SILO Pharma

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Tharimmune

Theriva Biologics

VivoSim Labs

Windtree Therapeutics, Inc. - Common Stock

Comments

Pasithea Therapeutics

Pasithea Therapeutics (KTTA) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL